Background: Heart exposure to ionizing irradiation can cause ischaemic heart disease. The partial heart volume receiving 5 Gy (heartV5) was supposed to be an independent prognostic factor for survival after radiochemotherapy for locally advanced non-small-cell lung cancer (NSCLC). But validation of the latter hypothesis is needed under the concurrent risks of lung cancer patients.
Introduction
Platin-based radiochemotherapy represents a standard of care for patients with stage IIIA/IIIB NSCLC [1, 2] . However, cumulative incidences of loco-regional progression approach 30% at longterm follow-up [2] . INT 0139 compared radiochemotherapy followed by surgery with definitive concurrent radiochemotherapy [3] . Without significant differences in overall survival, progression-free survival was found to be superior with trimodality. Dose escalation of radiotherapy was compared with standard dose radiotherapy in RTOG 0617 [4] . Concurrent carboplatin/ paclitaxel chemotherapy and consolidation chemotherapy were used, and the anti-EGFR antibody cetuximab was randomized as additional treatment.
Dose escalated radiotherapy (74 Gy) was not found to achieve superior survival compared with radiotherapy to 60 Gy. Radiation dose exposure of the heart, characterized by the partial heart volume receiving more than 5 Gy (heartV5) was supposed to be associated with adverse prognosis by an exploratory multivariate analysis [4] . Indeed, experimental studies showed that endothelial cells of the vasculature are considered the most radiosensitive structures of the heart and radiation can lead to arteriosclerosis and myocardial damage [5] . The hypothesis, that radiation exposure of the heart can affect survival of cancer patients by increasing the risk of ischaemic heart disease was supported by a large population-based case-control study on breast cancer patients resulting in a quantitative estimate of the dose-response relationship [6] .
The aim of the present analysis based on individual patient data of the prospective ESPATUE trial was to validate heartV5 as an independent prognostic factor for survival of patients with locally advanced NSCLC treated with concurrent radiochemotherapy. ESPATUE compared a trimodality treatment with definitive radiochemotherapy [7] . Hyperfractionated accelerated (AHF) radiotherapy was administered in both study arms in order to maximize loco-regional tumour control. No differences in overall survival or progression-free survival were found between treatment arms in ESPATUE, and overall survival of the randomized patients was 40%-44% at 5 years in both arms. Thus, the database of this study should be appropriately suited to detect a radiotherapy-dependent excess risk of death from cardiac disease.
Patients and methods

Patients
ESPATUE was a randomized trial enrolling patients with potentially resectable stage IIIA non-small-cell lung cancer (NSCLC) with N2 mediastinal involvement or selected stage IIIB NSCLC according to the UICC TNM classification, 6th edition [7, 8] . Following neoadjuvant radiochemotherapy patients were randomized to resection or immediate continuation of radiochemotherapy with a conventionally fractionated radiation boost as described in supplementary Material S1, available at Annals of Oncology online.
Statistical analysis
To prove that heartV5 is a major prognostic factor for survival after radiochemotherapy for locally advanced NSCLC due to induced heart toxicity, in a first step we analysed the power of the RTOG 0617 and ESPATUE data to detect the effect of heart radiation exposure on overall survival assuming the mean heart dose-effect relation posed by Darby et al. [6] . According to the latter, the radiation attributable annual risk of death from ischaemic heart disease is dependent on the baseline annual risk of the patient and the mean heart dose (MHD), i.e. excess risk ¼7.4%/Gy * mean heart dose * baseline risk (1) .
In a first step, the power of the ESPATUE data was evaluated to detect a radiation exposure dependent excess risk of death from ischaemic heart disease of the magnitude observed by the exploratory multivariable analysis of the RTOG 0617 data. Therefore, Monte Carlo simulations were done to determine the power of the ESPATUE and the RTOG 0617 trials at several annual base line risks of deaths from ischaemic cardiac disease by using observed overall survival data, the observed radiation exposures of the heart and by assuming relation (1) between radiation heart exposure and excess risk of death from ischaemic heart disease [9, 10] . The baseline risk corresponding to the observed hazard ratio for a percentage increase in heart V5 from multivariable proportional hazard analysis was thereby determined for the RTOG 0617 trial. If the power for the ESPATUE trial would be 80% at that baseline risk, a multivariable proportional hazard analysis of heart V5 as prognostic factor for survival would be performed adjusted for the same covariate set used in the analysis of RTOG 0617.
If an association of heartV5 with survival could not be substantiated, then an exploratory analysis was intended to further evaluate confounders of a relation between heartV5 and overall deaths or inter-current deaths without known tumour progression. The latter end point might be more closely related to death from ischaemic cardiac disease than overall survival.
Power analysis is described in supplementary Material S2, available at Annals of Oncology online.
Survival and death with progression were analysed as endpoints of this study. Proportional hazard analyses, correlation, regression, and analyses of variance were performed using SAS V R . Proportional hazard assumption for heartV5 and the linearity assumption of the dependence of the log hazard function on heartV5 were assessed by a Kolmogorov-type supremum test. The product limit method was used to estimate survival curves, a two-sided log-rank test was used to compare survival between groups. Cumulative incidence functions were compared by Gray's test.
Results
Patient and treatment dependent characteristics are presented in supplementary Material S3, available at Annals of Oncology online (including supplementary Table S1 and Figure S1 , available at Annals of Oncology online).
Power analyses for the detection of heartV5 as a prognostic factor for survival are depicted in Figure 1 showing a plot of the proportion of random samples revealing a significant association between heartV5 and overall survival by proportional hazard analysis at level of a ¼ 0.05 versus the baseline risk of annual death from ischaemic heart disease between 0% and 10% (200 data samples, fitted by logistic function, standard error of the power estimates 61.7%). The power increased with a baseline risk from 5% to >80% for both trials. Up to baseline risks of 2.5%, the power of both trials to detect heartV5 as a prognostic factor remained below 25%. The baseline risks associated with a power of 50% and 80% were 4.4% and 6.4% for simulations of the RTOG trial and 6.2% and 9.0% for ESPATUE ( Figure 1 ). An annual baseline risk of death from ischaemic heart disease of 9.5% corresponds to a hazard ratio of 1.007 per 1% increase in heartV5 for the RTOG trial under the simulation conditions used. At this baseline risk, the ESPATUE data set has a power of 80% for the detection of heartV5 as a prognostic factor.
The prognostic value of heartV5 was then analysed using multivariable proportional hazard analysis, including the same covariates as RTOG 0617: treatment arm, occurrence of oesophagitis grade 3, planning target volume (PTV), heartV5, ECOG performance status, gender, histologic subtype, smoking history (former/current smoker versus non-smoker). In addition, the recruiting institution was included as a covariate in the analysis. None of these covariates became significant and the hazard ratio per 1% increase in heartV5 was 1.005 (95% CI: 0.995-1.015, P ¼ 0.30). No deviations from the proportional hazard assumption (P ¼ 0.20) or from the linearity assumption of the log hazard dependence (P ¼ 0.33) were observed for heartV5. This hazard ratio corresponds to an annual base risk of cardiovascular mortality of 1.5% according to the parameters from ESPATUE. Therefore, the finding of RTOG 0617 that heartV5 is a major prognostic factor for survival could not be validated by the present analysis.
Univariable proportional hazard analysis did not show a significant influence of heartV5 on survival (Table 1) . In order to display the effect of heartV5, survival curves were plotted for groups of patients according to quartiles of the heartV5 distribution ( Figure 2A ). Due to longer median follow-up and favourable survival rates, the 72 months follow-up of the ESPATUE patients shown in Figure 2 results in 453 person-years at risk, and additional 74 person-years at risk were observed at longer follow-up time points. The 24 months follow-up of RTOG 0617 amounts to 629 person-years at risk.
Separating the death events into deaths without or with tumour progression leads to the cumulative incidence curves shown in Figure 2B and C. There was no influence of heartV5 on death without tumour progression, as shown in Figure 2B . Seven of the nine early deaths without progression within 12 months of follow-up were probably treatment related (pulmonary bleeding, pneumonia, septicemia). Four of the six deaths without progression occurring between 12 and 72 months of follow-up were due to secondary cancers. None of these 15 deaths were known to be caused by ischaemic heart disease. Figure 2C shows the cumulative incidence of deaths with tumour progression. At this end point, prognosis showed a stronger dependency on heartV5. Only 3 of the 66 deaths with progression before 72 months of follow-up displayed in Figure 2C were from cardiac events, two of them with heartV5 in quartile 4, and one in quartile3. The other causes of death were unknown, pneumonia, tumour progression, and others in 1, 6, 53, and 3 patients, respectively. In addition, multivariable analysis did not show a notable influence of heartV5 on death with progression (Table 1) . Overall, these observations do not support the hypothesis that heartV5 can substantially impair prognosis by increasing the risk of death from ischaemic heart disease under the exposure conditions and follow-up of ESPATUE.
The possibility that the small effect of heartV5 on survival might be due to the co-correlation with lower lobe tumour Figure 1. Power analyses for the RTOG 0617 data set and the ESPATUE data set for detection of heartV5 as a prognostic factor for survival by proportional hazard analysis in dependence on the baseline risk for death from ischaemic heart disease per year.HeartV5: partial heart volume receiving a radiation dose of 5 Gy. The data points for each trial were fitted by a logistic function. Hazard ratios for heartV5 are given per 1% increase in heartV5. a Multivariate proportional hazard analysis of the effect of heartV5 on survival or death with progression, adjusted for treatment arm assigned by randomization, presence of Grade III oesophagitis, ECOG status, gender, histologic subgroup, PTV, age, smoking history, recruiting institution. P-values for all the latter effect variables included for adjustment were 0.1. b Multivariate proportional hazard analysis of the effect of heartV5 and tumour location in the lower lobes on survival, adjusted for treatment arm assigned by randomization, presence of Grade III oesophagitis, ECOG status, gender, histologic subgroup, PTV, age, smoking history, recruiting institution and in addition tumour location in the lower lobes versus other lobes. P-values for all the latter effect variables included for adjustment were 0.1. HeartV5, partial volume of the heart receiving a total radiation dose of 5 Gy.
location was analysed by a second multivariable survival analysis introducing tumour location as an additional independent covariate which was associated with survival by a hazard ratio of 1.668 (95% CI: 0.948-3.282) in comparison to upper/middle lobe tumours and the hazard ratio for 1% increase in heartV5 dropped to 0.999 (95% CI: 0.986-1.012) in the presence of tumour location as an additional covariate (Table 1 ). Similar observations were found for death with progression. Therefore, heartV5 was not found to be an independent prognostic factor for survival or death with tumour progression.
Discussion
This study was intended to test the hypothesis that heartV5 is an independent prognostic factor for survival in patients with locally advanced NSCLC treated by radiochemotherapy due to radiation-induced cardiac toxicity. The latter was supported by an explorative analysis of RTOG 0617. On explorative multivariable analysis, factors predicting overall survival were radiation dose (60 Gy), maximum oesophagitis grade, the PTV, and heartV5 or heartV30. The present analysis based on individual patient data from the ESPATUE study could not confirm the hypothesis that heartV5 is an independent prognostic factor for survival in patients with locally advanced NSCLC treated by radiochemotherapy due to radiation-induced cardiac toxicity. The slight effect of heartV5 on survival or deaths with progression in univariable analysis disappeared in multivariable analysis. We found heartV5 highly depending on location of the primary tumour in the lower lobe. However, tumour location in the lower lobe might be an adverse prognostic factor independent of radiotherapy as it correlated with overall survival in a large retrospective study of patients with stage IB from the California Cancer Registry [11] . More than 90% of these patients were treated by surgery alone. A similar observation was obtained from other surgical series [12, 13] . A large retrospective MD Anderson Cancer Center data base on definitive radiochemotherapy for locally advanced NSCLC also failed to support heartV5 or MHD as independent prognostic factors for survival [14] . A significant association between MHD and an excess risk of ischaemic cardiovascular events was found by Darby et al. [6] in early breast cancer patients where the risk of death due to tumour progression is much lower than in locally advanced lung cancer. If the dose-response relation of that study holds also for lung cancer radiotherapy, then a baseline risk of fatal ischaemic heart disease of at least 4.4% per year or 6.4% per year is necessary to be detectable in trials as RTOG 0617 or ESPATUE. These baseline risks are higher than the risks found in several normal patients or lung cancer cohorts. For example, the baseline risk of death from ischaemic heart disease given by Darby was 0.3% per year in her highest risk group of women with at least one cardiac risk factor at the age of 70 years. Jairam et al. [15] found an annual death rate from coronary heart disease of 0.08% in smokers of a screening cohort for lung cancer at ages between 50 and 75 years. In a meta-analysis by Berry et al. [16] , the annual risk of death from all cardiovascular diseases was estimated at 1.7% per year in their highest risk group of men at 55 years of age with 2 major cardiovascular risk factors. Lung cancer patients have a higher risk of inter-current non-cancer death than patients with prostate or colorectal cancer and the maximum annual death rate from all non-cancer causes was estimated from Surveillance, Epidemiology, and End Results data at 4% per year [17] . Other series on resected patients have found annual death rates in a comparable range of 1.1%-6.6% [18, 19] . For the relations between the death incidences of ischaemic heart disease, all heart diseases and all causes, Ezzati et al. [20] found that deaths from ischaemic heart disease accounted for 60% of smoking-attributable cardiovascular deaths. The WHO mortality tabulation list [21] displays annual incidences of deaths from ischaemic heart disease, all heart diseases, and all causes of 0.17%, 0.24%, and 1.20%, respectively, for men of 60-64 years in Germany in 2010. In contrast to RTOG 0617, ESPATUE selected potentially resectable patients after induction chemotherapy and neoadjuvant radiochemotherapy. In general, such patients might be fitter and less comorbid than those included in RTOG 0617. Therefore, the baseline risk of fatal ischaemic cardiac disease in the ESPATUE population might be lower. Breathhold techniques, tumour tracking, intensity modulated radiotherapy and proton therapy can reduce cardiac volume in high-risk patients in comparison to 3D conformal radiotherapy [22] [23] [24] . Accordingly, the rationale of the presently recruiting RTOG 1308 trial is to test if proton therapy is able to improve overall survival of inoperable stage II-IIIB NSCLC patients in comparison to intensity modulated or 3D photon therapy by reducing the risk of severe toxicity. MHDs could be reduced by passively scattered proton therapy in comparison to intensity modulated photon therapy, but not mean lung or mean oesophagus dose, as found by a randomized trial from the MD Anderson Cancer Center for locally advanced NSCLC [22] .
These techniques could have measurable advantages in groups of patients with increased baseline risk of death from ischaemic heart disease especially with lower lobe tumours where MHDs are higher than for other locations.
Care has to be taken to prove that dose delivery by those alternative techniques is robust against cardiac motion [25] . The present study showed that the risk of death due to tumour progression is much higher than death from cardiac disease in the group of patients with operable stage III NSCLC. In conclusion, this analysis failed to support heartV5 as an important independent risk factor for death for patients treated with dose escalated definitive radiochemotherapy or neoadjuvant radiochemotherapy and resection following induction chemotherapy.
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